bionlp-st-ge-2016-test-ihmc  

PMC:1064895 / 15484-21991 JSONTXT 23 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue Speculation
T11586 9-14 Protein denotes IL-17
T11598 9-56 Gene_expression denotes IL-17 production in PBMC from patients with RA,
T11594 29-33 Entity denotes PBMC
T11577 53-56 Protein denotes RA,
T11579 71-73 Entity denotes OA
T11588 97-101 Entity denotes PBMC
T11589 135-148 Protein denotes PHA (5 μg/ml)
T11591 168-170 Protein denotes RA
T11584 186-188 Entity denotes OA
T11592 223-228 Protein denotes IL-17
T11582 260-284 Entity denotes the culture supernatants
T11576 286-289 Protein denotes Fig
T11596 316-340 Gene_expression denotes of basal IL-17 secretion
T11585 325-330 Protein denotes IL-17
T11590 368-370 Protein denotes RA
T11587 372-374 Entity denotes OA
T11597 447-485 Positive_regulation denotes the IL-17 production stimulated by PHA
T11595 447-485 Gene_expression denotes the IL-17 production stimulated by PHA
T11593 451-456 Protein denotes IL-17
T11578 479-485 Protein denotes by PHA
T11583 514-516 Protein denotes RA
T11581 514-521 Entity denotes RA PBMC
T11574 541-543 Entity denotes OA
T11580 592-593 Entity denotes P
T11575 622-623 Entity denotes P
T12335 636-702 Positive_regulation denotes Increased IL-17 production in PBMC of patients with RA by anti-CD3
T12315 646-651 Protein denotes IL-17
T12337 646-670 Gene_expression denotes IL-17 production in PBMC
T12323 666-670 Entity denotes PBMC
T12328 688-690 Protein denotes RA
T12310 694-702 Protein denotes anti-CD3
T12314 710-720 Protein denotes anti-CD28,
T12327 725-728 Protein denotes PHA
T12318 737-742 Protein denotes IL-17
T12329 807-824 Entity denotes activated T cells
T12326 881-912 Protein denotes of anti-CD3 (1, 5 and 10 μg/ml)
T12309 918-924 Entity denotes T cell
T12331 979-984 Protein denotes IL-17
T12320 1085-1093 Protein denotes anti-CD3
T12333 1104-1182 Positive_regulation denotes in Table 1, anti-CD3 significantly upregulated IL-17 production up to 3.7-fold
T12319 1116-1124 Protein denotes anti-CD3
T12316 1151-1156 Protein denotes IL-17
T12336 1151-1173 Gene_expression denotes IL-17 production up to
T12334 1188-1278 Gene_expression denotes the combination of anti-CD28 and anti-CD3 produced more IL-17 (approximately 1.3-1.5-fold)
T12312 1207-1216 Protein denotes anti-CD28
T12324 1221-1229 Protein denotes anti-CD3
T12321 1239-1278 Protein denotes more IL-17 (approximately 1.3-1.5-fold)
T12325 1279-1292 Protein denotes than anti-CD3
T12308 1333-1339 Entity denotes T cell
T12311 1333-1356 Entity denotes T cell mitogens such as
T12330 1333-1361 Protein denotes T cell mitogens such as PHA,
T12338 1362-1388 Gene_expression denotes increased IL-17 production
T12332 1362-1388 Positive_regulation denotes increased IL-17 production
T12322 1372-1377 Protein denotes IL-17
T12317 1419-1427 Protein denotes anti-CD3
T12313 1432-1441 Protein denotes anti-CD28
T13246 1486-1568 Regulation denotes Regulation of IL-17 production in RA PBMC by inflammatory cytokines and chemokines
T13245 1486-1568 Regulation denotes Regulation of IL-17 production in RA PBMC by inflammatory cytokines and chemokines
T13247 1497-1527 Gene_expression denotes of IL-17 production in RA PBMC
T13237 1500-1505 Protein denotes IL-17
T13216 1520-1522 Protein denotes RA
T13222 1520-1527 Entity denotes RA PBMC
T13225 1531-1553 Protein denotes inflammatory cytokines
T13231 1558-1568 Protein denotes chemokines
T13243 1577-1579 Protein denotes RA
T13224 1577-1584 Entity denotes RA PBMC
T13236 1593-1611 Entity denotes several cell types
T13230 1627-1635 Entity denotes T cells,
T13248 1654-1711 Regulation denotes cytokines released from macrophages and other lymphocytes
T13227 1654-1711 Protein denotes cytokines released from macrophages and other lymphocytes
T13244 1654-1768 Regulation denotes cytokines released from macrophages and other lymphocytes might have affected the production of IL-17 from T cells true
T13228 1678-1689 Entity denotes macrophages
T13229 1694-1711 Entity denotes other lymphocytes
T13251 1732-1768 Gene_expression denotes the production of IL-17 from T cells
T13223 1747-1755 Protein denotes of IL-17
T13213 1761-1768 Entity denotes T cells
T13249 1797-1847 Regulation denotes inflammatory cytokines released by activated PBMC,
T13232 1797-1847 Protein denotes inflammatory cytokines released by activated PBMC,
T13242 1829-1846 Entity denotes by activated PBMC
T13241 1873-1890 Protein denotes several cytokines
T13218 1895-1905 Protein denotes chemokines
T13212 1909-1914 Protein denotes IL-17
T13250 1909-1925 Gene_expression denotes IL-17 production
T13215 1954-1959 Protein denotes IL-17
T13220 1989-1994 Protein denotes IL-15
T13217 2020-2037 Protein denotes IL-1β (10 ng/ml),
T13214 2038-2054 Protein denotes TNF-α (10 ng/ml)
T13238 2056-2072 Protein denotes IL-18 (10 ng/ml)
T13239 2076-2092 Protein denotes TGF-β (10 ng/ml)
T13233 2107-2112 Protein denotes IL-17
T13219 2157-2173 Protein denotes MCP-1 (10 ng/ml)
T13211 2177-2181 Protein denotes IL-6
T13234 2223-2228 Protein denotes IL-17
T13226 2223-2237 Protein denotes IL-17 proteins
T13235 2351-2367 Protein denotes IL-8 (10 ng/ml),
T13221 2368-2385 Protein denotes MIP-1α (10 ng/ml)
T13240 2389-2406 Protein denotes MIP-1β (10 ng/ml)
T14369 2419-2483 Negative_regulation denotes Inhibition of IL-17 production by signal transduction inhibitors
T14365 2430-2449 Gene_expression denotes of IL-17 production
T14320 2433-2438 Protein denotes IL-17
T14342 2450-2483 Entity denotes by signal transduction inhibitors
T14339 2488-2508 Entity denotes anti-rheumatic drugs
T14359 2509-2567 Gene_expression denotes Having observed the increased IL-17 production in RA PBMC,
T14367 2525-2567 Positive_regulation denotes the increased IL-17 production in RA PBMC,
T14329 2539-2544 Protein denotes IL-17
T14328 2559-2561 Protein denotes RA
T14338 2559-2566 Entity denotes RA PBMC
T14327 2661-2664 Protein denotes Fig
T14361 2664-2742 Negative_regulation denotes . 3, an significant decrease in anti-CD3-induced IL-17 production was observed
T14358 2693-2729 Gene_expression denotes in anti-CD3-induced IL-17 production
T14352 2696-2712 Protein denotes anti-CD3-induced
T14354 2713-2718 Protein denotes IL-17
T14321 2766-2782 Entity denotes NF-κB inhibitor,
T14337 2792-2805 Entity denotes dexamethasone
T14322 2825-2833 Protein denotes anti-CD3
T14344 2907-2915 Entity denotes LY294002
T14330 2920-2930 Entity denotes wortmannin
T14319 2938-2956 Entity denotes inhibitor of PI3K,
T14368 2938-3029 Negative_regulation denotes inhibitor of PI3K, also markedly inhibited the anti-CD3-induced IL-17 production in RA PBMC
T14333 2951-2955 Protein denotes PI3K
T14360 2981-3018 Gene_expression denotes the anti-CD3-induced IL-17 production
T14334 2985-3001 Protein denotes anti-CD3-induced
T14349 3002-3007 Protein denotes IL-17
T14336 3022-3024 Protein denotes RA
T14316 3022-3029 Entity denotes RA PBMC
T14343 3116-3131 Protein denotes The calcineurin
T14348 3143-3156 Entity denotes cyclosporin A
T14366 3167-3274 Negative_regulation denotes also downregulated the IL-17 secretion as well as the mitogen-activated protein kinase (MAPK) p38 inhibitor
T14362 3186-3205 Gene_expression denotes the IL-17 secretion
T14340 3190-3195 Protein denotes IL-17
T14345 3217-3274 Entity denotes the mitogen-activated protein kinase (MAPK) p38 inhibitor
T14341 3217-3274 Protein denotes the mitogen-activated protein kinase (MAPK) p38 inhibitor
T14356 3221-3260 Protein denotes mitogen-activated protein kinase (MAPK)
T14325 3255-3259 Protein denotes MAPK
T14318 3297-3306 Entity denotes rapamycin
T14324 3311-3318 Entity denotes PD98059
T14323 3336-3341 Protein denotes IL-17
T14317 3390-3402 Entity denotes non-specific
T14331 3414-3425 Entity denotes by the drug
T14347 3492-3500 Entity denotes LY294002
T14364 3505-3547 Negative_regulation denotes the inhibition of IL-17 production in PBMC
T14357 3520-3539 Gene_expression denotes of IL-17 production
T14350 3523-3528 Protein denotes IL-17
T14326 3543-3547 Entity denotes PBMC
T14353 3590-3595 Protein denotes IL-17
T14363 3590-3641 Gene_expression denotes IL-17 production with chemical inhibitors (Fig. 4a)
T14332 3612-3641 Entity denotes chemical inhibitors (Fig. 4a)
T14351 3643-3696 Entity denotes The other inhibitors in addition to PDTC and LY294002
T14346 3688-3696 Entity denotes LY294002
T14335 3757-3761 Entity denotes PBMC
T14355 3765-3788 Entity denotes the chemical inhibitors
T14679 3850-3855 Protein denotes IL-17
T14683 3850-3860 Protein denotes IL-17 mRNA
T14695 3850-3882 Gene_expression denotes IL-17 mRNA expression in RA PBMC
T14681 3875-3877 Protein denotes RA
T14680 3875-3882 Entity denotes RA PBMC
T14694 3898-3923 Positive_regulation denotes enhanced IL-17 production
T14692 3898-3923 Gene_expression denotes enhanced IL-17 production
T14693 3898-3969 Regulation denotes enhanced IL-17 production could be regulated at a transcriptional level true
T14678 3907-3912 Protein denotes IL-17
T14686 4090-4115 Protein denotes in IL-17 mRNA transcripts
T14684 4090-4115 Protein denotes in IL-17 mRNA transcripts
T14691 4093-4098 Protein denotes IL-17
T14689 4139-4147 Protein denotes anti-CD3
T14688 4171-4198 Entity denotes the PI3K inhibitor LY294002
T14682 4171-4198 Entity denotes the PI3K inhibitor LY294002
T14687 4175-4179 Protein denotes PI3K
T14685 4210-4225 Entity denotes NF-κB inhibitor
T14690 4232-4235 Protein denotes Fig
T15431 4253-4324 Protein denotes of PI3K/Akt signal transduction pathway on IL-17 production by anti-CD3
T15440 4253-4324 Protein denotes of PI3K/Akt signal transduction pathway on IL-17 production by anti-CD3
T15426 4313-4324 Protein denotes by anti-CD3
T15439 4338-4388 Entity denotes downstream effector molecules of the PI3K pathway,
T15435 4349-4357 Entity denotes effector
T15433 4371-4387 Protein denotes the PI3K pathway
T15446 4389-4443 Positive_regulation denotes we evaluated the activation of Akt by western blotting
T15429 4417-4423 Protein denotes of Akt
T15444 4494-4513 Protein denotes anti-CD3 (10 μg/ml)
T15428 4517-4525 Entity denotes LY294002
T15432 4552-4585 Protein denotes the amounts of phosphorylated Akt
T15427 4652-4675 Protein denotes Akt increased (lane 2),
T15425 4705-4725 Entity denotes by LY294002 (lane 3)
T15434 4789-4811 Protein denotes non-phosphorylated Akt
T15449 4789-4811 Phosphorylation denotes non-phosphorylated Akt
T15442 4816-4823 Protein denotes β-actin
T15430 4874-4877 Protein denotes PHA
T15448 4874-4983 Regulation denotes PHA, concanavalin A and IL-15 also demonstrated the same effect on phosphorylated Akt as shown with anti-CD3,
T15437 4879-4893 Protein denotes concanavalin A
T15438 4898-4903 Protein denotes IL-15
T15447 4938-4959 Phosphorylation denotes on phosphorylated Akt
T15441 4938-4959 Protein denotes on phosphorylated Akt
T15436 4974-4983 Protein denotes anti-CD3,
T15443 5011-5021 Entity denotes wortmannin
T15445 5045-5070 Entity denotes LY294002 (data not shown)
T16776 5073-5127 Positive_regulation denotes Activation of the NF-κB and activator protein-1 (AP-1)
T16775 5073-5127 Positive_regulation denotes Activation of the NF-κB and activator protein-1 (AP-1)
T16758 5087-5096 Protein denotes the NF-κB
T16755 5101-5120 Protein denotes activator protein-1
T16759 5122-5126 Protein denotes AP-1
T16760 5139-5164 Entity denotes the IL-17 promoter region
T16745 5143-5148 Protein denotes IL-17
T16732 5188-5205 Entity denotes the intracellular
T16762 5237-5245 Protein denotes anti-CD3
T16728 5251-5292 Protein denotes anti-CD28, concanavalin A, PHA and IL-15,
T16733 5262-5276 Protein denotes concanavalin A
T16720 5278-5281 Protein denotes PHA
T16766 5286-5291 Protein denotes IL-15
T16764 5322-5327 Protein denotes IL-17
T16773 5322-5339 Gene_expression denotes IL-17 expression,
T16768 5403-5408 Protein denotes NF-κB
T16765 5403-5426 Entity denotes NF-κB recognition sites
T16751 5430-5452 Entity denotes the promoters of IL-17
T16757 5447-5452 Protein denotes IL-17
T16726 5466-5469 Protein denotes Fig
T16746 5475-5553 Entity denotes nuclear extracts from RA PBMC stimulated with anti-CD3 plus anti-CD28 (lane 2)
T16771 5475-5612 Binding denotes nuclear extracts from RA PBMC stimulated with anti-CD3 plus anti-CD28 (lane 2) demonstrated increased binding of NF-κB to IL-17 promoters
T16735 5497-5499 Protein denotes RA
T16752 5497-5553 Entity denotes RA PBMC stimulated with anti-CD3 plus anti-CD28 (lane 2)
T16748 5521-5529 Protein denotes anti-CD3
T16721 5535-5553 Protein denotes anti-CD28 (lane 2)
T16772 5567-5612 Positive_regulation denotes increased binding of NF-κB to IL-17 promoters
T16729 5585-5593 Protein denotes of NF-κB
T16727 5594-5612 Entity denotes to IL-17 promoters
T16770 5597-5602 Protein denotes IL-17
T16754 5708-5711 Protein denotes p65
T16730 5716-5719 Protein denotes p50
T16734 5743-5757 Protein denotes c-Rel (lane 5)
T16723 5762-5773 Entity denotes normal PBMC
T16761 5823-5828 Protein denotes NF-κB
T16780 5823-5866 Positive_regulation denotes NF-κB activation by anti-CD3 plus anti-CD28
T16779 5823-5866 Positive_regulation denotes NF-κB activation by anti-CD3 plus anti-CD28
T16724 5843-5851 Protein denotes anti-CD3
T16739 5857-5866 Protein denotes anti-CD28
T16749 5897-5899 Protein denotes RA
T16743 5897-5904 Entity denotes RA PBMC
T16740 5906-5909 Protein denotes Fig
T16738 5944-5948 Protein denotes PI3K
T16741 5962-5967 Protein denotes NF-κB
T16718 6053-6061 Entity denotes LY294002
T16719 6090-6095 Protein denotes NF-κB
T16767 6120-6148 Entity denotes the IL-17 promoter (Fig. 7c)
T16769 6124-6129 Protein denotes IL-17
T16725 6171-6176 Protein denotes IκB-α
T16774 6177-6230 Negative_regulation denotes showed inhibition of degradation of IκB-α by LY294002
T16777 6195-6218 Protein_catabolism denotes of degradation of IκB-α
T16742 6210-6218 Protein denotes of IκB-α
T16737 6219-6230 Entity denotes by LY294002
T16753 6258-6261 Protein denotes Fig
T16731 6281-6297 Protein denotes the AP-1 pathway
T16722 6336-6344 Protein denotes anti-CD3
T16750 6350-6359 Protein denotes anti-CD28
T16736 6392-6402 Protein denotes that NF-κB
T16763 6415-6428 Entity denotes intracellular
T16744 6450-6455 Protein denotes IL-17
T16778 6450-6506 Gene_expression denotes IL-17 production by activated PBMC from patients with RA
T16756 6467-6484 Entity denotes by activated PBMC
T16747 6504-6506 Protein denotes RA
R6297 T11578 T11597 causeOf by PHA,the IL-17 production stimulated by PHA
R6298 T11585 T11596 themeOf IL-17,of basal IL-17 secretion
R6299 T11586 T11598 themeOf IL-17,"IL-17 production in PBMC from patients with RA,"
R6300 T11593 T11595 themeOf IL-17,the IL-17 production stimulated by PHA
R6301 T11595 T11597 themeOf the IL-17 production stimulated by PHA,the IL-17 production stimulated by PHA
R6721 T12315 T12337 themeOf IL-17,IL-17 production in PBMC
R6722 T12316 T12336 themeOf IL-17,IL-17 production up to
R6723 T12319 T12333 causeOf anti-CD3,"in Table 1, anti-CD3 significantly upregulated IL-17 production up to 3.7-fold"
R6724 T12321 T12334 themeOf more IL-17 (approximately 1.3-1.5-fold),the combination of anti-CD28 and anti-CD3 produced more IL-17 (approximately 1.3-1.5-fold)
R6725 T12322 T12338 themeOf IL-17,increased IL-17 production
R6726 T12336 T12333 themeOf IL-17 production up to,"in Table 1, anti-CD3 significantly upregulated IL-17 production up to 3.7-fold"
R6727 T12337 T12335 themeOf IL-17 production in PBMC,Increased IL-17 production in PBMC of patients with RA by anti-CD3
R6728 T12338 T12332 themeOf increased IL-17 production,increased IL-17 production
R7228 T13212 T13250 themeOf IL-17,IL-17 production
R7229 T13223 T13251 themeOf of IL-17,the production of IL-17 from T cells
R7230 T13225 T13246 causeOf inflammatory cytokines,Regulation of IL-17 production in RA PBMC by inflammatory cytokines and chemokines
R7231 T13227 T13244 causeOf cytokines released from macrophages and other lymphocytes,cytokines released from macrophages and other lymphocytes might have affected the production of IL-17 from T cells
R7232 T13227 T13248 themeOf cytokines released from macrophages and other lymphocytes,cytokines released from macrophages and other lymphocytes
R7233 T13231 T13245 causeOf chemokines,Regulation of IL-17 production in RA PBMC by inflammatory cytokines and chemokines
R7234 T13232 T13249 themeOf "inflammatory cytokines released by activated PBMC,","inflammatory cytokines released by activated PBMC,"
R7235 T13237 T13247 themeOf IL-17,of IL-17 production in RA PBMC
R7236 T13242 T13249 causeOf by activated PBMC,"inflammatory cytokines released by activated PBMC,"
R7237 T13247 T13245 themeOf of IL-17 production in RA PBMC,Regulation of IL-17 production in RA PBMC by inflammatory cytokines and chemokines
R7238 T13247 T13246 themeOf of IL-17 production in RA PBMC,Regulation of IL-17 production in RA PBMC by inflammatory cytokines and chemokines
R7239 T13251 T13244 themeOf the production of IL-17 from T cells,cytokines released from macrophages and other lymphocytes might have affected the production of IL-17 from T cells
R7922 T14319 T14368 causeOf "inhibitor of PI3K,","inhibitor of PI3K, also markedly inhibited the anti-CD3-induced IL-17 production in RA PBMC"
R7923 T14320 T14365 themeOf IL-17,of IL-17 production
R7924 T14329 T14359 themeOf IL-17,"Having observed the increased IL-17 production in RA PBMC,"
R7925 T14340 T14362 themeOf IL-17,the IL-17 secretion
R7926 T14342 T14369 causeOf by signal transduction inhibitors,Inhibition of IL-17 production by signal transduction inhibitors
R7927 T14349 T14360 themeOf IL-17,the anti-CD3-induced IL-17 production
R7928 T14350 T14357 themeOf IL-17,of IL-17 production
R7929 T14353 T14363 themeOf IL-17,IL-17 production with chemical inhibitors (Fig. 4a)
R7930 T14354 T14358 themeOf IL-17,in anti-CD3-induced IL-17 production
R7931 T14357 T14364 themeOf of IL-17 production,the inhibition of IL-17 production in PBMC
R7932 T14358 T14361 themeOf in anti-CD3-induced IL-17 production,". 3, an significant decrease in anti-CD3-induced IL-17 production was observed"
R7933 T14359 T14367 themeOf "Having observed the increased IL-17 production in RA PBMC,","the increased IL-17 production in RA PBMC,"
R7934 T14360 T14368 themeOf the anti-CD3-induced IL-17 production,"inhibitor of PI3K, also markedly inhibited the anti-CD3-induced IL-17 production in RA PBMC"
R7935 T14362 T14366 themeOf the IL-17 secretion,also downregulated the IL-17 secretion as well as the mitogen-activated protein kinase (MAPK) p38 inhibitor
R7936 T14365 T14369 themeOf of IL-17 production,Inhibition of IL-17 production by signal transduction inhibitors
R8121 T14678 T14692 themeOf IL-17,enhanced IL-17 production
R8122 T14683 T14695 themeOf IL-17 mRNA,IL-17 mRNA expression in RA PBMC
R8123 T14692 T14693 themeOf enhanced IL-17 production,enhanced IL-17 production could be regulated at a transcriptional level
R8124 T14692 T14694 themeOf enhanced IL-17 production,enhanced IL-17 production
R8527 T15429 T15446 themeOf of Akt,we evaluated the activation of Akt by western blotting
R8528 T15434 T15449 themeOf non-phosphorylated Akt,non-phosphorylated Akt
R8529 T15441 T15447 themeOf on phosphorylated Akt,on phosphorylated Akt
R8530 T15441 T15448 themeOf on phosphorylated Akt,"PHA, concanavalin A and IL-15 also demonstrated the same effect on phosphorylated Akt as shown with anti-CD3,"
R9175 T16724 T16779 causeOf anti-CD3,NF-κB activation by anti-CD3 plus anti-CD28
R9176 T16727 T16770 partOf to IL-17 promoters,IL-17
R9177 T16727 T16771 themeOf to IL-17 promoters,nuclear extracts from RA PBMC stimulated with anti-CD3 plus anti-CD28 (lane 2) demonstrated increased binding of NF-κB to IL-17 promoters
R9178 T16729 T16771 themeOf of NF-κB,nuclear extracts from RA PBMC stimulated with anti-CD3 plus anti-CD28 (lane 2) demonstrated increased binding of NF-κB to IL-17 promoters
R9179 T16737 T16774 causeOf by LY294002,showed inhibition of degradation of IκB-α by LY294002
R9180 T16739 T16780 causeOf anti-CD28,NF-κB activation by anti-CD3 plus anti-CD28
R9181 T16742 T16777 themeOf of IκB-α,of degradation of IκB-α
R9182 T16744 T16778 themeOf IL-17,IL-17 production by activated PBMC from patients with RA
R9183 T16755 T16776 themeOf activator protein-1,Activation of the NF-κB and activator protein-1 (AP-1)
R9184 T16758 T16775 themeOf the NF-κB,Activation of the NF-κB and activator protein-1 (AP-1)
R9185 T16761 T16779 themeOf NF-κB,NF-κB activation by anti-CD3 plus anti-CD28
R9186 T16761 T16780 themeOf NF-κB,NF-κB activation by anti-CD3 plus anti-CD28
R9187 T16764 T16773 themeOf IL-17,"IL-17 expression,"
R9188 T16767 T16769 partOf the IL-17 promoter (Fig. 7c),IL-17
R9189 T16771 T16772 themeOf nuclear extracts from RA PBMC stimulated with anti-CD3 plus anti-CD28 (lane 2) demonstrated increased binding of NF-κB to IL-17 promoters,increased binding of NF-κB to IL-17 promoters
R9190 T16777 T16774 themeOf of degradation of IκB-α,showed inhibition of degradation of IκB-α by LY294002